Open Access

Perspectives on results from recent CVOTs in type 2 diabetes.

Topic: Diabetes, dysglycaemia and metabolic syndrome
Sponsored by Novo Nordisk

Presentation

About the speaker

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)
31 presentations
0 follower

4 more presentations in this session

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

Speaker: Professor L. Ryden (Stockholm, SE)

Thumbnail

Cardiovascular effects of GLP-1 receptor agonists.

Speaker: Doctor J. Plutzky (Boston, US)

Thumbnail

Results from the LEADER cardiovascular outcomes trial.

Speaker: Professor N. Poulter (London, GB)

Thumbnail

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Speaker: Professor L. Ryden (Stockholm, SE) Doctor J. Plutzky (Boston, US) Professor N. Poulter (London, GB)

Thumbnail

Access the full session

Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Speakers: Professor L. Ryden, Professor L. Ryden, Doctor J. Plutzky, Professor N. Poulter, Professor L. Ryden...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk